Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis

References

• Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician. 2010;81:1440–1446.
   PubMed Web of Science ®Google Scholar
• Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6:11–23.
   PubMed Web of Science ®Google Scholar
• Garcia-Mozo H. Poaceae pollen as the leading aeroallergen worldwide: A review. Allergy. 2017 May 22. doi: 10.1111/all.13210. [Epub ahead of print]
   Google Scholar
• Blaiss MS. Allergic rhinitis in schoolchildren consensus group. Allergic rhinitis and impairment issues in schoolchildren: A consensus report. Curr Med Res Opin. 2004;20:1937–1952.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22:1203–1210.
   PubMed Web of Science ®Google Scholar
• Uzzaman A, Story R. Chapter 5: allergic rhinitis. Allergy Asthma Proc. 2012;33(Suppl 1):S15–S18.
   PubMedGoogle Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381–387.
   PubMed Web of Science ®Google Scholar
• World Allergy Organization. WAO white book on allergy update 2013. Milwaukee, WI: World Allergy Organization; 2014.
   Google Scholar
• Devillier P, Bousquet J, Salvator H, et al. In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures. Clin Exp Allergy. 2016;46:1456–1464.
   PubMed Web of Science ®Google Scholar
• Marseglia GL, Merli P, Caimmi D, et al. Nasal disease and asthma. Int J Immunopathol Pharmacol. 2011;24:7–12.
   PubMed Web of Science ®Google Scholar
• Williams DC, Edney G, Maiden B, et al. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J. 2013;6:4.
   PubMedGoogle Scholar
• Tsilochristou OA, Douladiris N, Makris M, et al. Pediatric allergic rhinitis and asthma: can the march be halted? Paediatr Drugs. 2013;15:431–440.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
   PubMedGoogle Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556–568.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11:1321–1333.
   PubMed Web of Science ®Google Scholar
• Didier A, Wahn U, Horak F, et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014;10:1309–1324.
   PubMed Web of Science ®Google Scholar
• Scaparrotta A, Attanasi M, Petrosino MI, et al. Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis. Drug Des Devel Ther. 2015;9:5897–5909.
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–725.
   Google Scholar
• Calamita Z, Saconato H, Pela AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61:1162–1172.
   PubMed Web of Science ®Google Scholar
• Erny-Albrecht K, Valentine WJ, Christensen J, et al. Sublingual immunotherapy in allergic rhinitis and asthma: a review of recent clinical evidence. J Appl Res. 2007;7:17–31.
   Google Scholar
• Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014;69:1181–1188.
   PubMed Web of Science ®Google Scholar
• Bell H, Wailoo AJ, Hernandez M et al. NICE Decision Support Unit: the use of real world data for the estimation of treatment effects in NICE decision making. 2016. cited 2017 Aug. Available at: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/RWD-DSU-REPORT-Updated-DECEMBER-2016.pdf
   Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375:2293–2297.
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28:18–29.
   PubMed Web of Science ®Google Scholar
• Mahajan R. Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res. 2015;5:82.
   PubMedGoogle Scholar
• Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2017 May 31. doi: 10.1111/all.13213. [Epub ahead of print]
   Google Scholar
• Frieden TR. Evidence for health decision making – beyond randomized, controlled trials. N Engl J Med. 2017;377:465–475.
   PubMed Web of Science ®Google Scholar
• Richter H, Dombrowski S, Hamer H, et al. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci. 2015;13:Doc14.
   PubMedGoogle Scholar
• Indication of flowering periods of various allergenic pollen types in Germany 2007-2011. Stiftung Deutscher Informationsdienst, 2016. cited 2017 Aug. Available from: http://www.pollenstiftung.de/pollenvorhersage/pollenflug-kalender/
   Google Scholar
• Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma, 2015. [cited 2017 Aug]. Available from: http://ginasthma.org/
   Google Scholar
• Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129–138.
   PubMed Web of Science ®Google Scholar
• Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017 Sep 13. doi: 10.1111/pai.12807 [Epub ahead of print]
   Google Scholar
• Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101:206–211.
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851–857.
   PubMed Web of Science ®Google Scholar
• Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2017 Jul 6. pii: S0091–6749(17)31088-6. doi: 10.1016/j.jaci.2017.06.014. [Epub ahead of print]
   Google Scholar
• Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy. 2014;44:986–998.
   PubMed Web of Science ®Google Scholar
• Chabre H, Gouyon B, Huet A, et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy. 2010;40:505–519.
   PubMed Web of Science ®Google Scholar
• Worm M, Lee HH, Kostev K. Prevalence and treatment profile of patients with grass pollen and house dust mite allergy. J Dtsch Dermatol Ges. 2013;11:653–661.
   PubMed Web of Science ®Google Scholar
• Bachert C, Van Cauwenberge P, Olbrecht J, et al. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006;61:693–698.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schwarz K, Stadler E, et al. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015;136:1511–1516.
   PubMed Web of Science ®Google Scholar
• Arasi S, Pajno GB. Pre-coseasonal vs perennial sublingual immunotherapy for seasonal allergens dosing regimen: long-term benefits, adherence, and cost-effectiveness – is there a difference? Curr Treat Options Allergy. 2016;3:93–101.
   Google Scholar